Effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology.

Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for Medicare & Medicaid Services (CMS) that establish significant reimbursement for coronary plaque analysis using PlaqueIQ across care settings.

The first and only CT-based plaque analysis indicated for the carotid anatomy that can help physicians assess risk of rupture and ischemic stroke 1 BOSTON - October 29, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise...

BOSTON – August 11, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced that United Healthcare has updated its cardiac imaging guidelines...

Leaders in clinical, product innovation, and market access will provide guidance for PlaqueIQTM strategy BOSTON and SCCT ANNUAL MEETING, MONTREAL – July 17, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of...

New reimbursement recommendations support earlier, non-invasive identification of high-risk cardiovascular patients BOSTON – July 15, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive...

Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques BOSTON – July 10, 2025 – Elucid, an AI medical technology company focused on providing physicians with a...

Cardiac CT Expert to Advance Research and Commercialization of Company’s PlaqueIQTM Image Analysis Software BOSTON – July 7, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive...

BOSTON – March 3, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added several senior members to its clinical and commercial teams. The...

Noridian latest MAC to make Elucid PlaqueIQTM image analysis software available for eligible patients BOSTON – October 25, 2024 – Elucid has announced that Noridian will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared...

New policy to make company’s PlaqueIQTM image analysis software available to eligible patients with suspected coronary artery disease BOSTON – October 15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend...